Efficacy and Safety of New Generation Drug Eluting Stents Associated With an Ultra Short Duration of Dual Antiplatelet Therapy. Design of the Short Duration of Dual antiplatElet Therapy With SyNergy II Stent in Patients Older Than 75 Years Undergoing Percutaneous Coronary Revascularization.

Inclusion Criteria:

• 1- Patient is ≥ 75 years old
• 2- One or more significant coronary artery stenosis is/are present (defined as ≥70% byvisual assessment or ≥50% with Fractional Flow Reserve <0.80) or a left main coronarystenosis ≥50% by visual assessment) suitable for PCI with one of the followingpresent:
• a -Silent ischemia,
• stress-induced myocardial ischemia ≥ 10% of myocardium in a asymptomatic patient or
• stress-induced myocardial ischemia < 10% of myocardium AND FFR (Fractional FlowReserve) ≤0.80 or
• b - Stable angina, in a patient with objective ischemia despite optimal medicaltherapy or
• c - acute coronary syndrome including: unstable angina, non ST- and ST elevationmyocardial infarction.
• 3- All patients must also sign informed consent as per local law and comply with allstudy process during follow up for at least one year.

Exclusion Criteria:

• 1- The subject is not eligible for randomization if ANY of the following is present:
• 2- Indication for myocardial revascularization by coronary artery bypass grafting,
• 3- Subjects unable to tolerate, obtain or comply with dual antiplatelet therapy for atleast one month (stable angina or silent ischemia) or at least six month (acutecoronary syndrome),
• 4- Subjects requiring additional surgery (cardiac or non-cardiac) within one month,
• 5- Non cardiac co-morbidities with life expectancy less than 1 year,
• 6- Prior hemorrhagic stroke,
• 7- Known allergy to aspirin or P2Y12 inhibitors,
• 8- At least one contra indication to ALL the authorized P2Y12 inhibitors at therequested dose (in case of contra indication to only one of two of the P2Y12inhibitors, the investigators are allowed to use the P2Y12 inhibitors for which noallergy is known).
• 9- Silent ischemia <10% of the myocardium with FFR ≥0.80.
• 10- Participation in another clinical trial